# Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

> **NCT05614349** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 797 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Paxlovid
- **DRUG:** Antioxidant

## Key facts

- **NCT ID:** NCT05614349
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-16
- **Primary completion:** 2025-04-28
- **Final completion:** 2025-06-28
- **Target enrollment:** 797 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05614349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05614349, "Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05614349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*